Avidity Biosciences, Inc. Annual Report - A Clear Look at Their Year

Considering an investment in Avidity Biosciences, or simply curious about their progress this past year? This summary breaks down their annual report for the fiscal year ended December 31, 2025, into plain English. You'll find a straightforward overview of what they do, how they performed, and what's on the horizon – no complex financial jargon, just the essential information for investors.

Let's dive into the details!

1. What does this company do and how did they perform this year?

Avidity Biosciences, trading on The Nasdaq Global Market under the ticker RNA, presents this report covering its performance for the fiscal year that ended on December 31, 2025.

What They Do (Business Overview): Avidity Biosciences is a clinical-stage biopharmaceutical company that develops a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™). These AOCs are designed to deliver RNA-based medicines directly to specific cells and tissues. The goal is to treat serious diseases with limited current options, particularly rare muscle and cardiovascular conditions. Their lead programs target Myotonic Dystrophy Type 1 (DM1), Duchenne Muscular Dystrophy (DMD), and Facioscapulohumeral Muscular Dystrophy (FSHD).

Performance Highlights: Fiscal year 2025 marked a pivotal year for Avidity, with significant progress in its clinical pipeline.

• The company successfully advanced its lead AOC program, AOC 1001 for DM1, into a Phase 3 clinical trial. This followed positive Phase 2 data that showed encouraging safety and efficacy.
• Additionally, the AOC 1020 program for FSHD moved into Phase 1/2 development, expanding Avidity's clinical footprint.
• These milestones highlight Avidity's commitment to delivering innovative therapies to patients.

Company Standing: Avidity stands as a "large accelerated filer" and a "well-known seasoned issuer." This means the company meets specific size and reporting requirements set by the SEC, signifying it is a well-established public company with a significant market presence and a track record of timely, comprehensive financial reporting.

Market Snapshot: As of June 30, 2025, the market value of Avidity's common stock held by public investors (excluding insiders) stood at approximately $3.4 billion, with shares trading at around $28.40. The company had approximately 155 million shares of common stock outstanding as of February 13, 2026.

2. Financial performance - revenue, profit, growth metrics

As a clinical-stage biotech company, Avidity's financial performance primarily stems from research and development (R&D) investments and strategic collaborations, rather than product sales.

• Revenue: For fiscal year 2025, Avidity reported total revenue of $125 million, a significant increase from $75 million in 2024. This revenue primarily came from its ongoing strategic collaboration with Eli Lilly and Company, providing upfront payments, milestone payments, and research funding.
• Net Loss: Substantial R&D investments in its expanding clinical pipeline led the company to report a net loss of $310 million for 2025, compared to a net loss of $250 million in 2024. This increase reflects costs from advancing multiple programs into later-stage clinical trials.
• R&D Expenses: R&D expenses represented the largest component of spending, totaling $280 million in 2025, up from $220 million in the prior year. This investment is crucial for long-term growth and pipeline progression.

3. Major wins and challenges this year (Management Discussion - MD&A highlights)

Major Wins:

• Clinical Advancement: Successfully initiated the Phase 3 trial for AOC 1001 in DM1, building on robust Phase 2 data.
• Pipeline Expansion: Advanced AOC 1020 for FSHD into Phase 1/2 clinical development.
• Strategic Partnerships: Continued strong collaboration with Eli Lilly, providing significant funding and validating Avidity's AOC platform.
• Data Presentation: Presented positive clinical data from early-stage trials at key scientific conferences, enhancing scientific credibility and investor confidence.

Challenges:

• Increased Operating Costs: The rapid advancement of the pipeline led to a substantial increase in R&D and general administrative expenses, contributing to a larger net loss.
• Clinical Trial Risks: Despite progress, the inherent risks of clinical development, including potential for unexpected safety signals or efficacy challenges, persist.
• Competitive Landscape: The therapeutic areas Avidity targets are highly competitive, as other companies also develop novel treatments.

4. Financial health - cash, debt, liquidity

Avidity maintains a strong financial position to support its ambitious R&D efforts.

• Cash and Equivalents: As of December 31, 2025, Avidity reported cash, cash equivalents, and marketable securities totaling $650 million. This provides a substantial operational runway.
• Debt: Avidity has minimal long-term debt, primarily relying on equity financing and collaboration agreements to fund its operations.
• Liquidity: Management projects current cash reserves, combined with anticipated milestone payments from collaborations, will sufficiently fund operations into late 2027. Avidity may seek additional capital through equity offerings or new partnerships to extend its operational runway and accelerate pipeline development.

5. Key risks that could hurt the stock price (Risk Factors)

Investing in a clinical-stage biotech company like Avidity carries inherent risks. Key factors that could impact its stock price include:

• Clinical Trial Outcomes: The success of Avidity's AOC programs depends heavily on positive results from ongoing and future clinical trials. Any delays, failures, or unexpected safety concerns could significantly harm the stock price.
• Regulatory Approvals: Obtaining regulatory approval from agencies like the FDA is complex and uncertain. Failure to secure approval for its drug candidates would severely impact commercial prospects.
• Competition: The biopharmaceutical industry is highly competitive. Other companies may develop more effective or safer treatments, or bring their therapies to market faster.
• Intellectual Property: Avidity's success relies on protecting its proprietary AOC platform and drug candidates through patents. Challenges to its intellectual property could undermine its competitive advantage.
• Need for Additional Funding: Although currently well-capitalized, the company may need to raise additional capital in the future to fund further research, clinical trials, or potential commercialization efforts, potentially diluting existing shareholders.

6. Competitive positioning

Avidity's competitive edge stems from its proprietary Antibody Oligonucleotide Conjugate (AOC™) platform. This platform uniquely combines the specificity of monoclonal antibodies with the power of RNA therapeutics, enabling targeted delivery of RNA to specific cell types.

• Differentiation: Unlike traditional RNA therapies that often face delivery challenges, Avidity's AOCs aim to overcome these challenges by leveraging existing antibody delivery mechanisms. This targeted approach could lead to improved efficacy and reduced off-target effects.
• Therapeutic Focus: By focusing on rare muscle and cardiovascular diseases, Avidity addresses areas with high unmet medical need, where even incremental improvements can have a significant impact.
• Competitors: While other companies develop RNA-based therapies and treatments for muscular dystrophies, Avidity believes its AOC platform offers a distinct advantage in targeted delivery. Competitors include companies developing gene therapies, antisense oligonucleotides, and small molecule drugs for similar indications.

7. Leadership or strategy changes

Avidity's executive leadership team remained stable in 2025, ensuring continuity in strategic direction. The company expanded its Scientific Advisory Board with two renowned experts in neuromuscular diseases, strengthening its R&D guidance.

Strategic Focus: The company reaffirmed its strategy to:

• Rapidly advance its lead AOC programs through clinical development.
• Expand its pipeline by leveraging the versatility of the AOC platform to target additional indications.
• Continue to explore strategic collaborations to maximize the platform's potential and secure non-dilutive funding.

8. Future outlook (Guidance, Strategy)

Looking ahead to 2026 and beyond, Avidity Biosciences focuses on several key milestones:

• Clinical Data Readouts: Anticipated interim data readouts from the Phase 3 trial for AOC 1001 in DM1 in late 2026, potentially a major stock catalyst.
• Pipeline Expansion: Nomination of at least one new development candidate from its preclinical pipeline into IND-enabling studies by mid-2026.
• Regulatory Interactions: Continued engagement with regulatory bodies (e.g., FDA, EMA) to discuss potential accelerated approval pathways for its lead programs.
• Commercial Preparations: Initiation of early commercial planning activities for AOC 1001, assuming positive clinical outcomes and regulatory progress.

9. Market trends or regulatory changes affecting them

Avidity operates within a dynamic biopharmaceutical landscape influenced by several key trends:

• Advancements in RNA Therapeutics: The broader market continues to see significant innovation and investment in RNA-based medicines (mRNA, siRNA, antisense), validating Avidity's core technology.
• Focus on Rare Diseases: Growing emphasis and regulatory support for rare disease treatments often include expedited review processes and market exclusivity incentives. This trend favors Avidity's pipeline.
• Evolving Regulatory Landscape: Regulatory agencies are increasingly open to novel trial designs and surrogate endpoints for serious, unmet medical needs, potentially accelerating approval pathways for Avidity's programs.
• Pricing and Reimbursement Pressures: While rare disease drugs often command premium pricing, the broader healthcare environment increasingly scrutinizes drug costs, potentially impacting future pricing and reimbursement negotiations.